All News

An angiotensin II receptor blocker that is used to treat high blood pressure has been recalled due to a contamination that carries a potential cancer risk; with insurance companies considering precision medicine experimental, the high cost of a promising area of medicine may be out of reach for patients; instead of using a local pharmacy, employees of the state of Utah could be paid to go to Mexico to fill their prescriptions.

Over the past several decades, the number of patients who survive head and neck cancer (HNC) has increased; among the more than 15 million cancer survivors in the United States, approximately 430,000 (3%) are survivors of HNC. These survivors may face persistent and late effects of their diagnosis and treatment that increase psychological morbidity, including suicidal ideation.

As with other kinds of surgery, patients undergoing operations for breast cancer can experience persistent postsurgical pain, which can negatively affect quality of life. Researchers in Tokyo conducted a study to see if they could determine the predictive value and accuracy of an acute pain trajectory, measured by pain intensity at 1 day after the surgery and pain prevalence at 6 months later.

The National Institutes of Health is suspending human testing of an experimental, taxpayer-funded, stem cell trial for heart failure in light of emerging questions about the scientific foundation for the treatment; Republicans are working to shift the national healthcare conversation by telling seniors their Medicare coverage may be in danger; the drive to tighten immigration rules is stirring concerns in the medical profession about how it will affect the future supply of doctors in the United States.

Lalan Wilfong, MD, moderated a conversation between Robert E. Baird, MD, CEO of Dayton Physicians Network, and Sarah Cevallos, chief revenue cycle officer for Florida Cancer Specialists and Research Institute, about current and future strategies for Oncology Care Model (OCM) participation, as well as key lessons from the OCM and how they can be applied in other reform models.

Guidelines indicate that high-risk patients with polycythemia vera (PV) should be treated with phlebotomy and cytoreductive therapy—such as hydroxyurea or interferon-alfa—to reduce the risk of thrombosis, the major cause of death among patients with PV. To assess the effectiveness of these treatment modalities among older US adults with PV, the authors of a newly published paper evaluated a large cohort of patients with PV in the real-world setting.

A small biotech company is moving toward FDA approval with a pill it believes can lower bad cholesterol at a discount to other medicines; most of the nation’s hospitals have so far avoided offering any form of addiction medicine to patients in the emergency department, but in Maryland, that is starting to change; since 2010, nearly 90 rural hospitals have shut their doors, and there are consequences for residents and different reasons why this is happening.

Brand Logo

259 Prospect Plains Rd, Bldg H
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences®

All rights reserved.

Secondary Brand Logo